Panion & BF Biotech is set to expand the global footprint of its new drug Nephoxil, with General Manager Chiang, Tsung-Ming announcing on December 2 that the active pharmaceutical ingredient (API), pharmaceutical-grade ferric citrate, has been submitted for Drug Master File (DMF) registration in the United States. A new production facility is scheduled to commence operations in the fourth quarter of 2025, with an initial annual capacity of 50 tons, aiming to reach 100 tons by 2027. This is expected to become the company's new "cash cow," driving its next phase of growth.

Panion & BF Biotech emphasized that the new facility will establish the largest global capacity for pharmaceutical-grade ferric citrate APIs. The company, which has been a pioneer in this field, previously supported raw material supply chains in Japan and the United States. With its long-standing expertise and world-class efficiency, Panion & BF Biotech continues to expand its market presence across Asia. Demand for APIs is surging, and the company aims to become the second or third supplier for U.S. and Japanese clients.

The second-generation API offers a competitive edge, enabling the production of tablets comparable in size to rival products. Taiwan, which previously utilized capsules, is now transitioning to tablet forms similar to those in Japan and the U.S. In the Asia-Pacific region, ferric citrate has become a dominant option, gradually replacing traditional calcium-based phosphate binders and polymer-based agents like Sevelamer.

Over the past decade, usage of calcium-based phosphate binders, polymer-based treatments, and combination therapies has declined, while market penetration for iron-based phosphate binders has surged from 10% to 32.9%. Ferric citrate, with its dual phosphate-lowering and iron-supplementing capabilities, has emerged as the leading iron-based binder.

Despite competition from generics in the U.S., Nephoxil's market prospects remain promising due to its potential qualification for Transitional Drug Add-On Payment Adjustments (TDAPA), increasing market coverage from 40% to nearly 100%. In Japan, where generic competition has not yet emerged, sales grew by 9% last year. In Europe, regulatory submissions were made in 2024, with approval targeted for the first half of 2025.

In Asia, market expansion continues:

• In South Korea, distributor transitions are underway.
• In Thailand, regulatory approval has been secured this year.
• In China, the drug is under regulatory review.
• Additional Southeast Asian markets will see submissions in Q4 2024, further broadening Nephoxil's global presence.

In Taiwan, a 1,000 mg tablet and new indications for Nephoxil are expected to be submitted for regulatory approval and parallel health insurance reimbursement review by the end of this year.

From a demand perspective:

• Japan, with approximately 350,000 dialysis patients, accounts for an annual demand of 15–30 tons, representing a market share of 15–17% for Panion & BF Biotech’s licensing partner.
• Europe exhibits demand similar to Japan.
• The United States presents an even larger market.

The combined demand from these three regions exceeds 100 tons annually, and growing demand in Asia-Pacific—particularly in South Korea, China, and Thailand—further strengthens the outlook.

The new facility, set to begin operations in Q4 2025, will prioritize supplying the Asia-Pacific market, followed by the U.S., Europe, and Japan. This development is poised to position Panion & BF Biotech for sustained growth, with the API becoming a cornerstone of its revenue stream.

Resource: 新Cash cow！寶齡富錦原料藥明年Q4投產，2027年產能衝百噸